|
Pfizer and BioNTech receive U.S. FDA Emergency Use Authorization of COVID-19 vaccine booster for individuals 12 years of age and older
|
04 January 2022 |
|
Pfizer and BioNTech provide update on Omicron variant
|
08 December 2021 |
|
AWS helps Pfizer accelerate drug development and clinical manufacturing
|
02 December 2021 |
|
Pfizer to provide U.S. government with 10 million treatment courses of investigational oral antiviral candidate to help combat COVID-19
|
18 November 2021 |
|
Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of Phase 2/3 EPIC-HR study
|
05 November 2021 |
|
Pfizer and BioNTech announce Phase 3 trial data showing high efficacy of a booster dose of their COVID-19 vaccine
|
25 October 2021 |
|
Pfizer and BioNTech receive first U.S. FDA Emergency Use Authorization of a COVID-19 vaccine booster
|
24 September 2021 |
|
Pfizer and BioNTech announce positive topline results from pivotal trial of COVID-19 vaccine in children 5 to 11 years
|
21 September 2021 |
|
Pfizer and BioNTech announce submission of initial data to U.S. FDA to support booster dose of COVID-19 vaccine
|
16 August 2021 |
|
VTX-801 receives U.S. FDA Fast Track designation for the treatment of Wilson Disease
|
13 August 2021 |
|
Pfizer and BioNTech to provide U.S. government with an additional 200 million doses of COVID-19 vaccine
|
28 July 2021 |
|
Pfizer and BioNTech announce collaboration with Biovac to manufacture and distribute COVID-19 vaccine doses within Africa
|
21 July 2021 |
|
Collaboration between AbbVie, Biogen and Pfizer creates world's largest browsable resource linking rare protein-coding genetic variants to human health and disease
|
15 July 2021 |
|
Pfizer and BioNTech to supply the European Union with up to 1.8 billion additional doses of COMIRNATY®
|
26 May 2021 |
|
Pfizer and BioNTech to provide COVID-19 caccine doses for olympic athletes at the 2020 Tokyo Games
|
06 May 2021 |
|
Pfizer acquires Amplyx Pharmaceuticals
|
28 April 2021 |
|
Pfizer-BioNTech announce positive topline results of pivotal COVID-19 vaccine study in adolescents
|
31 March 2021 |
|
Pfizer initiates Phase 1 study of novel oral antiviral therapeutic agent against SARS-CoV-2
|
24 March 2021 |
|
Real-world evidence confirms high effectiveness of Pfizer-BioNTech COVID-19 vaccine and profound public health impact of vaccination one year after pandemic declared
|
11 March 2021 |
|
Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
|
25 February 2021 |